Division of Pediatric Hemato-Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria.
St. Anna Kinderkrebsforschung, Children's Cancer Research Institute, CCRI, Vienna, Austria.
J Med Genet. 2020 Jun;57(6):427-433. doi: 10.1136/jmedgenet-2019-106339. Epub 2019 Nov 8.
The phenotypes of patients with the recently discovered, dominant, -linked leukaemia predisposition and familial thrombocytopenia syndrome are variable, and the exact mechanism of leukaemogenesis remains unclear. Here, we present novel clinical and laboratory phenotypes of seven individuals from three families with germline mutations and a refined genetic analysis of one child with additional high-hyperdiploid acute lymphoblastic leukaemia (HD-ALL), aiming to elucidate second oncogenic hits. Four individuals from two pedigrees harboured one novel or one previously described variant in the central domain of (c.592C>T, p.Gln198* or c.641C>T, p.Pro241Leu, respectively). Neutropenia was an accompanying feature in one of these families that also harboured a variant in (c.1098_1103dup, p.Ile366_Gly367dup), while in the other, an autism-spectrum disorder was observed. In the third family, the index patient suffered from HD-ALL and life-threatening pulmonary mucor mycosis, and had a positive family history of 'immune' thrombocytopenia. Genetic analyses revealed a novel heterozygous mutation in the ETS domain of (c.1136T>C, p.Leu379Pro) along with absence of heterozygosity of chromosome (10)(q21.2q21.3), yielding a biallelic leukaemia risk allele in (rs7090445-C). The neutrophil function was normal in all individuals tested, and the platelet immune histochemistry of all three pedigrees showed delta-storage-pool defect-like features and cytoskeletal defects. Our clinical observations and results of high-resolution genetic analyses extend the spectrum of possible phenotypes cosegregating with germline mutations. Further, we propose as potential leukaemogenic cofactor in patients with -linked leukaemia predisposition and familial thrombocytopenia syndrome.
新发现的显性连锁白血病易感性和家族性血小板减少症综合征患者的表型多种多样,白血病发生的确切机制仍不清楚。在这里,我们介绍了三个家系的 7 名个体的新的临床和实验室表型,这些个体具有种系突变,并对另一名患有附加高超二倍体急性淋巴细胞白血病(HD-ALL)的儿童进行了精细的遗传分析,旨在阐明第二致癌打击。两个家系的 4 名个体分别携带一种新的或以前描述过的 (c.592C>T,p.Gln198*或 c.641C>T,p.Pro241Leu)中央结构域的变体。其中一个家系伴有中性粒细胞减少症,该家系还携带 (c.1098_1103dup,p.Ile366_Gly367dup)的变体,而另一个家系则观察到自闭症谱系障碍。在第三个家系中,先证者患有 HD-ALL 和危及生命的肺毛霉病,并具有“免疫性”血小板减少症的阳性家族史。遗传分析显示 ETS 结构域中存在一种新的杂合突变 (c.1136T>C,p.Leu379Pro),同时缺失染色体(10)(q21.2q21.3)的杂合性,导致 (rs7090445-C)中的白血病风险等位基因呈双等位基因。所有测试的个体的中性粒细胞功能均正常,三个家系的血小板免疫组织化学均显示δ储存池缺陷样特征和细胞骨架缺陷。我们的临床观察和高分辨率遗传分析结果扩展了与 种系突变共分离的可能表型谱。此外,我们提出 可能是具有显性连锁白血病易感性和家族性血小板减少症综合征的患者的潜在白血病致癌协同因子。